{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Complete Response (CR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Near Complete Response (nCR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Very Good Partial Response (VGPR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Partial Response (PR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Minor Response (MR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Stable Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"description":"This outcome measure was to determine the response rate along with attainment of stable disease and time to disease progression following treatment with this patient population. The response rates were defined as follows.\n\nA complete response (CR) was defined as having resolution of all symptoms, normalization of serum IgM levels with complete disappearance of IgM paraprotein by immunofixation, absence of bone marrow disease by bone marrow biopsy and aspiration, and resolution of any adenopathy or splenomegaly. A near complete response (nCR) was defined as fulfilling all CR criteria in the presence of a positive immunofixation study. Patients with very good partial response (VGPR), partial response (PR), and minor response (MR) were defined as having a ≥ 90%, ≥ 50%, and 25% to 49% reduction in serum IgM levels, respectively. Progressive disease (PD) occurred when a more than 25% increase in serum IgM level or progression of clinically significant disease parameters was observed.","groups":[{"description":"A cycle of therapy consisted of bortezomib 1.3 mg/m(2) intravenously; dexamethasone 40 mg on days 1, 4, 8, and 11; and rituximab 375 mg/m(2) on day 11. Patients received four consecutive cycles for induction therapy and then four more cycles, each given 3 months apart, for maintenance therapy.","id":"OG000","title":"Bortezomib, Dexamethasone, Rituximab"}],"paramType":"NUMBER","populationDescription":"all enrolled patients","reportingStatus":"POSTED","timeFrame":"33.2 months","title":"Response Rate","type":"PRIMARY","unitOfMeasure":"participants"}